Rutgers, the State University of New Jersey

University of Medicine and Dentistry of New Jersey

Sergei V Kotenko

Grant E Gallagher

Viralkumar Rameshkumar Davra

Grant F Gallagher

Raymond B Birge

Joan E Durbin

Geoffrey L Smith

Fusion molecules of a cytokine or portion thereof and a polypeptide which targets the fusion protein to phosphatidylserine, pharmaceutical compositions thereof, and methods for their use in targeting a cytokine or portion thereof to a pathological site and treating a disease or condition responsive to cytokine treatment are provided.

Phosphatidylserine targeting fusion molecules and methods for their use

Fusion molecules composed of a type I interferon protein or portion thereof and a type III interferon protein or portion thereof, pharmaceutical compositions containing the fusion molecules, and methods for their use in inhibiting infection, inhibiting or treating cancer, inducing signaling of transcription of IFN-stimulated genes through an IFN-&#x3b1;R2 chain in a subject suffering from an infection which degrades or downregulates an IFN-&#x3b1;R1 chain, and treating various diseases or conditions are provided.

Type I and type III interferon fusion molecules and methods for use thereof

A novel IFN-&#x3b1;/&#x3b2; independent ligand receptor system which upon engagement leads, among other things, to the establishment of an anti-viral state is disclosed. Further disclosed are three closely positioned genes on human chromosome 19 that encode distinct but highly homologous proteins, designated IFN-&#x3bb;1, IFN-&#x3bb;2, IFN-&#x3bb;3, based inter alia, in their ability to induce antiviral protection. Expression of these proteins is induced upon viral infection. A receptor complex utilized by all three IFN-&#x3bb; proteins for signaling is also disclosed. The receptor complex is generally composed of two subunits, a novel receptor designated IFN-&#x3bb;R1 or CRF2-12, and a second subunit, IL-10R2 or CRF2-4, which is also a shared receptor component for the IL-10 and IL-22 receptor complexes. The gene encoding IFN-&#x3bb;R1 is generally widely expressed, including many different cell types and tissues. Expression of these proteins is induced by immune events, including, for example, upon viral infection. Apoptotosis may also be induced under effective conditions.

Methods for increasing levels of interferon activity with an interferon lambda 3 polypeptide

A novel IFN-&#x3b1;/&#x3b2; independent ligand receptor system which upon engagement leads, among other things, to the establishment of an anti-viral state is disclosed. Further disclosed are three closely positioned genes on human chromosome 19 that encode distinct but highly homologous proteins, designated INF-&#x3bb;1, IFN-&#x3bb;2, IFN-&#x3bb;3, based inter alia, in their ability to induce antiviral protection. Expression of these proteins is induced upon viral infection. A receptor complex utilized by all three IFN-&#x3bb; proteins for signaling is also disclosed. The receptor complex is generally composed of two subunits, a novel receptor designated IFN-&#x3bb;R1 or CRF2-12, and a second subunit, IL-10R2 or CRF2-4, which is also a shared receptor component for the IL-10 and IL-22 receptor complexes. The gene encoding IFN-&#x3bb;R1 is generally widely expressed, including many different cell types and tissues. Expression of these proteins is induced by immune events, including, for example, upon viral infection. Apoptotosis may also be induced under effective conditions.

Method for increasing interferon activity in an individual

Described are compositions and methods useful for modulating the immune system of a subject. Also included are diagnostic methods for monitoring an immunologic condition. In particular the invention relates to antagonists of interferon proteins and associated methods of use as well as methods to develop neutralizing antibodies against IFN antagonists to treat viral infections.

Interferon antagonists, antibodies thereto and associated methods of use

A novel IFN-&#x3b1;/&#x3b2; independent ligand receptor system which upon engagement leads, among other things, to the establishment of an anti-viral state is disclosed. Further disclosed are three closely positioned genes on human chromosome 19 that encode distinct but highly homologous proteins, designated IFN-&#x3bb;1, IFN-&#x3bb;2, IFN-&#x3bb;3, based, inter alia, in their ability to induce antiviral protection. Expression of these proteins is induced upon viral infection. A receptor complex utilized by all three IFN-&#x3bb; proteins for signaling is also disclosed. The receptor complex is generally composed of two subunits, a novel receptor designated IFN-&#x3bb;R1 or CRF2-12, and a second subunit, IL-10R2 or CRF2-4, which is also a shared receptor component for the IL-10 and IL-22 receptor complexes. The gene encoding IFN-&#x3bb;R1 is generally widely expressed, including many different cell types and tissues. Expression of these proteins is induced by immune events, including, for example, upon viral infection. Apoptotosis may also be induced under effective conditions.

Growing community of inventors

East Brunswick, NJ, United States of America

Sergei V Kotenko